Method of treating hyperproliferative diseases using active vitamin D analogues

• US 6,680,309 B2
• Filed: 01/07/2003
• Issued: 01/20/2004
• Est. Priority Date: 12/30/1996
• Status: Expired due to Fees

• Current Assignee: Bone Care International LLC
• Original Assignee: Bone Care International LLC
• Inventors: Bishop, Charles W., Mazess, Richard B.
• Primary Examiner(s): Reamer, James H
• Application Number:
  US10/337,506
• Publication Number:
  US 20030130242A1
• Time in Patent Office: 378 Days
• Field of Search: 514/167, 514/188
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Claims

1. A method of inhibiting hyperproliferation of cancers of the breast, colon, lung, neck, head, pancreas, endometrium, bladder, cervix, testes, ovaries and liver, comprising treating the cells with an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound having a hydrocarbon moiety at the C-24 position, the cells expressing a vitamin D receptor.

2. The method in accordance with claim 1, wherein the method inhibits cancers of the breast.

3. The method in accordance with claim 1, wherein the method inhibits cancers of the colon.

4. The method in accordance with claim 1, wherein the method inhibits cancers of the lung.

5. The method in accordance with claim 1, wherein the method inhibits cancers of the neck.

6. The method in accordance with claim 1, wherein the method inhibits cancers of the head.

7. The method in accordance with claim 1, wherein the method inhibits cancers of the pancreas.

8. The method in accordance with claim 1, wherein the method inhibits cancers of the endometrium.

9. The method in accordance with claim 1, wherein the method inhibits cancers of the bladder.

10. The method in accordance with claim 1, wherein the method inhibits cancers of the cervix.

11. The method in accordance with claim 1, wherein the method inhibits cancers of the testes.

12. The method in accordance with claim 1, wherein the method inhibits cancers of the ovaries.

13. The method in accordance with claim 1, wherein the method inhibits cancers of the liver.

14. A method of inhibiting hyperproliferation of cancers of squamous cell carcinoma, myeloid leukemia, lymphocytic leukemia, lymphoma, medullary thyroid carcinoma, melanoma, multiple myeloma, retinoblastoma, sarcomas of the soft tissues and sarcomas of the bone, comprising treating the cells with an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound having a hydrocarbon moiety at the C-24 position, the cells expressing a vitamin D receptor.

15. The method in accordance with claim 14, wherein the method inhibits cancers of squamous cell carcinoma.

16. The method in accordance with claim 14, wherein the method inhibits cancers of myeloid leukemia.

17. The method in accordance with claim 14, wherein the method inhibits cancers of lymphocytic leukemia.

18. The method in accordance with claim 14, wherein the method inhibits lymphomas.

19. The method in accordance with claim 14, wherein the method inhibits medullary thyroid carcinomas.

20. The method in accordance with claim 14, wherein the method inhibits melanomas.

21. The method in accordance with claim 14, wherein the method inhibits multiple myelomas.

22. The method in accordance with claim 14, wherein the method inhibits cancers of retinoblastoma.

23. The method in accordance with claim 14, wherein the method inhibits sarcomas of the soft tissues.

24. The method in accordance with claim 14, wherein the method inhibits sarcomas of the bone.

25. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound, wherein the hypocalcemic vitamin D compound is administered in a daily regimen.

26. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound, wherein the hypocalcemic vitamin D compound is administered in an episodic regimen.

27. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound, wherein the hypocalcemic vitamin D compound is administered intravenously, is directly injected to a cancer site or is regionally delivered to a cancer site.

28. The method in accordance with claim 27, wherein the hypocalcemic vitamin D compound is administered intravenously.

29. The method in accordance with claim 27, wherein the hypocalcemic vitamin D compound is directly injected to a cancer site.

30. The method in accordance with claim 27, wherein the hypocalcemic vitamin D compound is regionally delivered to a cancer site.

31. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound, wherein the hypocalcemic vitamin D compound is co-administered with a cytotoxic agent selected from the group consisting of an antimetabolite, an antimicrotubule agent, and an alkylating agent.

32. The method in accordance with claim 31, wherein the cytotoxic agent is an antimetabolite.

33. The method in accordance with claim 31, wherein the cytotoxic agent is an antimicrotubule agent.

34. The method in accordance with claim 31, wherein the cytotoxic agent is an alkylating agent.

35. A method of inhibiting the hyperproliferative activity of malignant or neoplastic cells, comprising administering to a patient suffering therefrom, an antiproliferative amount of a hypocalcemic hydroxyvitamin D compound, wherein the hypocalcemic vitamin D compound is co-administered with a cytotoxic agent selected from the group consisting of a platinum agent, an anthracycline, a topoisomase inhibitor, or an antibiotic.

36. The method in accordance with claim 35, wherein the cytotoxic agent is a platinum agent.

37. The method in accordance with claim 35, wherein the cytotoxic agent is an anthracycline.

38. The method in accordance with claim 35, wherein the cytotoxic agent is a topoisomase inhibitor.

39. The method in accordance with claim 35, wherein the cytotoxic agent is an antibiotic.

40. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of a hypocalcemic hydroxyvitamin D selected from a group consisting of 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, and 1α

,25-dihydroxyvitamin D₄.

41. The method in accordance with claim 40, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₂.

42. The method in accordance with claim 40, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₄.

43. The method in accordance with claim 40, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₂.

44. The method in accordance with claim 40, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₄.

45. A method of inhibiting hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of a hypocalcemic hydroxyvitamin D selected from a group consisting of 1α

-hydroxyvitamin D₂ or 1α

-hydroxyvitamin D₄.

46. The method in accordance with claim 45, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₂.

47. The method in accordance with claim 45, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₄.

48. A method of treating a human to alleviate the pathological effects of breast cancer, colon cancer, testicular cancer, pancreatic cancer, endometrial cancer, small cell cancer of the lung, squamous cell cancer of the lung, adneocarcinoma cell cancer of the lung, squamous cell cancer of the head, squamous cell cancer of the neck, bladder cancer, ovarian cancer and cervical cancer, comprising administering to the human an therapeutic amount of a hypocalcemic hydroxyvitamin D compound.

49. The method in accordance with claim 48, to alleviate the pathological effects of breast cancer.

50. The method in accordance with claim 48, to alleviate the pathological effects of colon cancer.

51. The method in accordance with claim 48, to alleviate the pathological effects of testicular cancer.

52. The method in accordance with claim 48, to alleviate the pathological effects of pancreatic cancer.

53. The method in accordance with claim 48, to alleviate the pathological effects of endometrial cancer.

54. The method in accordance with claim 48, to alleviate the pathological effects of small cell cancers of the lung.

55. The method in accordance with claim 48, to alleviate the pathological effects of squamous cell cancer of the lung.

56. The method in accordance with claim 48, to alleviate the pathological effects of adneocarcinoma cell cancer of the lung.

57. The method in accordance with claim 48, to alleviate the pathological effects of squamous cell cancer of the head.

58. The method in accordance with claim 48, to alleviate the pathological effects of squamous cell cancer of the neck.

59. The method in accordance with claim 48, to alleviate the pathological effects of bladder cancer.

60. The method in accordance with claim 48, to alleviate the pathological effects of ovarian cancer.

61. The method in accordance with claim 48, to alleviate the pathological effects of cervical cancer.

73. The method of claim of claim 48 wherein the hypocalcemic hydroxyvitamin D is selected from the group consisting of 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, 1α

,25-dihydroxyvitamin D₄, 1α

-hydroxyvitamin D₂ or 1α

-hydroxyvitamin D₄.

74. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₂.

75. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₄.

76. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₂.

77. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₄.

78. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₂.

79. The method in accordance with claim 73, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₄.

62. A method of treating a human to alleviate the pathological effects of myeloid leukemia, lymphocyltic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma, retinoblastoma, sarcomas of the soft tissue and sarcomas of the bone, comprising administering to the human an therapeutic amount of a hypocalcemic hydroxyvitamin D compound.

63. The method in accordance with claim 62, to alleviate the pathological effects of myeloid leukemia.

64. The method in accordance with claim 62, to alleviate the pathological effects of lymphocytic leukemia.

65. The method in accordance with claim 62, to alleviate the pathological effects of lymphoma.

66. The method in accordance with claim 62, to alleviate the pathological effects of hepatic tumors.

67. The method in accordance with claim 62, to alleviate the pathological effects of medullary thyroid carcinoma.

68. The method in accordance with claim 62, to alleviate the pathological effects of multiple myeloma.

69. The method in accordance with claim 62, to alleviate the pathological effects of melanoma.

70. The method in accordance with claim 62, to alleviate the pathological effects of retinoblastoma.

71. The method in accordance with claim 62, to alleviate the pathological effects of sarcomas of the soft tissue.

72. The method in accordance with claim 62, to alleviate the pathological effects of sarcomas of the bone.

80. The method of claim of claim 62 wherein the hypocalcemic hydroxyvitamin D is selected from the group consisting of 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂, 1α

,25-dihydroxyvitamin D₄, 1α

-hydroxyvitamin D₂ and 1α

-hydroxyvitamin D₄.

81. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₂.

82. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₄.

83. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₂.

84. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₄.

85. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₂.

86. The method in accordance with claim 80, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₄.

87. A method of enhancing the antiproliferative effect of a cytotoxic agent in a patient with a disease in need of treatment by a cytotoxic agent, comprising administering to the patient a therapeutic amount of a hypocalcemic vitamin D selected from the group consisting of 1α

,24-dihydroxyvitamin D₂, 1α

,24-dihydroxyvitamin D₄, 1α

,25-dihydroxyvitamin D₂ and 1α

,25-dihydroxyvitamin D₄, and the cytotoxic agent.

88. The method in accordance with claim 87, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₂.

89. The method in accordance with claim 87, wherein the hypocalcemic hydroxyvitamin D is 1α

,24-dihydroxyvitamin D₄.

90. The method in accordance with claim 87, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₂.

91. The method in accordance with claim 87, wherein the hypocalcemic hydroxyvitamin D is 1α

,25-dihydroxyvitamin D₄.

92. A method of enhancing the antiproliferative effect of a cytotoxic agent in a patient with a disease in need of treatment by a cytotoxic agent, comprising administering to the patient a therapeutic amount of a hypocalcemic vitamin D selected from the group consisting of 1α

-hydroxyvitamin D₂ and 1α

-hydroxyvitamin D₄, and the cytotoxic agent.

93. The method in accordance with claim 92, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₂.

94. The method in accordance with claim 92, wherein the hypocalcemic hydroxyvitamin D is 1α

-hydroxyvitamin D₄.

95. A method of enhancing the antiproliferative effect of a cytotoxic agent in a patient with a disease in need of treatment by a cytotoxic agent, comprising administering to the patient a therapeutic amount of a hypocalcemic vitamin D and a cytotoxic agent selected from the group consisting of an antimetabolite, an antimicrotubule agent, and an alkyating agent.

96. The method in accordance with claim 95, wherein the cytotoxic agent is an antimetabolite.

97. The method in accordance with claim 95, wherein the cytotoxic agent is an antimicrotubule agent.

98. The method in accordance with claim 95, wherein the cytotoxic agent is an alkylating agent.

99. A method of enhancing the antiproliferative effect of a cytotoxic agent in a patient with a disease in need of treatment by a cytotoxic agent, comprising administering to the patient a therapeutic amount of a hypocalcemic vitamin D and a cytotoxic agent selected from the group consisting of a platinum agent, an anthracycline, a topoisomase inhibitor, or an antibiotic.

100. The method in accordance with claim 99, wherein the cytotoxic agent is a platinum agent.

101. The method in accordance with claim 99, wherein the cytotoxic agent is an anthracycline.

102. The method in accordance with claim 99, wherein the cytotoxic agent is a topoisomase inhibitor.

103. The method in accordance with claim 99, wherein the cytotoxic agent is an antibiotic.